Colby, Juvaris deal

Colby received exclusive, worldwide rights to develop and commercialize Juvaris' Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100 for non-veterinary use. Colby will develop the products to target infectious diseases and inflammation. Juvaris will receive an undisclosed upfront payment and is eligible for milestones and royalties.

Juvaris said it completed its strategy of out-licensing its adjuvanted vaccines and immunotherapies and now becomes a virtual entity with an IP portfolio covering the CLDC technology and JVRS-100. The virtual company will be managed by CEO Grant Pickering and CFO Kimberlee Gonzaga. ...